Figure 3. Visualisation of ESMO-MCB scores for curative and non-curative setting. A & B and 5 and 4 represent the grades with substantial improvement.

Slides:

Advertisements

Similar presentations

From: An open day in the metric space

Advertisements

Fig. 3. Plot of overall survival by adjuvant therapy for patient subgroups. (A) Patients with M0 disease (n = 411). (B) Patients receiving 36 Gy craniospinal.

Fig. 1 Flow chart of the COBRA-light trial and its extension study

From: Global Banking: Recent Developments and Insights from Research*

Figure 2. Quality of life (QOL) scores for functional scale items

Figure 1. FinHER dataset: distribution of tumor-infiltrating lymphocytes in breast cancer according to the (A) three breast cancer subtypes and (B) HER2.

Figure 1. Dose modification scheme for the second cycle of capecitabine treatment. From: Adjuvant capecitabine chemotherapy using a tailored-dose strategy.

Figure 1. Scree plot for the exploratory factor analysis (EFA) of the Death Depression Scale (DDS). From: Development and psychometric evaluation of a.

Figure 2. CONSORT flow diagram.

Fig. 3 Evolutionary game types as a function of relatedness and synergy where each plot is a different social group size. The payoffs used to generate.

Figure 1 Cumulative chance of pregnancy according to age at initiation of pregnancy seeking. The curves were drawn based on the following assumptions:

Figure 1. Mean recalled time (days) since the start of the last quit attempt by use of stop-smoking medications (SSM) and Heaviness of Smoking Index (HSI)

pSS: primary SS; Scl: scleroderma.

Fig. 1 Flow chart of study selection

Figure 1. Conceptual model of well-being related to involvement in theatre. From: Theatre Involvement and Well-Being, Age Differences, and Lessons From.

Figure 1. (A) Forest plot of common odds ratios (adjusted for ECOG PS) for best overall response by a priori subgroups in patients with KRAS wild-type.

Figure 1. Orthodontic set-up and location of LLLT or placebo-laser

From: Face Recognition is Shaped by the Use of Sign Language

Figure 2. Illustration of minimum cross-sectional area (a) and measurements for oropharynx and soft palate in sagittal plane (b, c). From: Airway volume.

Fig. 1. Geographic locations of Shenzhen and Dongguan

Figure 1 (A) Chest computed tomography scans of the patient

Figure 2. (A) Sézary syndrome patient before treatment

Figure 2. Kaplan–Meier survival analysis in patients

Figure 1 Flow chart showing the selection of publications identified in the literature search. From: GnRH antagonist versus long agonist protocols in IVF:

Fig. 1. Timeline of the CPAP in Ghana study.

From: Where do we go from here

From: A European Disease

Figure 1. Overall survival of patients receiving alternative medicine (solid lines) vs conventional cancer treatment (dashed lines). Overall survival of.

Example 14. Schubert, Quartet in G Major, D

Figure 1 Prevalence of functional mitral regurgitation according to NYHA functional class (A; P

Fig. 1 Selection of patients

Figure 1 Study flowchart.

Figure 1. Orthodontic set-up and location of LLLT or placebo-laser

Figure 1. Examples of e-cigarette discussions in social media

From: Estimating the Location of World Wheat Price Discovery

Figure 1. Time of initiation of therapeutic hypothermia according to who initiated it. Note the logarithmic scaling of the vertical axis. From: Initiation.

Figure 1. Publication channels used by scholars at the faculty of Arts, 2006–2013. From: Accountability in context: effects of research evaluation systems.

Figure 1: Time points at which sperm samples were analysed for aneuploidy frequencies in controls and cancer patients From: Sperm aneuploidy frequencies.

Figure 1: Logistic regression showing association of prescribing provider and patient panel characteristics with occurrence of a hospitalization or ED.

Figure 1. Dosage and administration route of drugs used in the BMD study. Each cycle was proposed every 28 days (‘base’ schedule) or 35 days (‘weekly’

Figure 1. Percentage of trainees is represented on the y-axis for each competency/knowledge item represented in the x-axis. Only Poor/Fair (P/F) ratings.

Figure 1. (A) Cumulative risk of breast (diamonds) and ovarian (squares) cancer in BRCA1 mutation carriers. (B) Cumulative risk of breast (diamonds) and.

Figure 6. RRs for clinical cure rates stratified by different diseases

Figure 1. Progression-free survival and overall survival for FL/DLBCL patients. From: Clinicobiological features and prognostic impact of diffuse large.

Figure 1. Patterns of HER2–PET/CT confronted with FDG–PET/CT, Maximum intensity projection. Lesion uptake was considered pertinent when visually higher.

توزیع جغرافیایی مرگ به دلیل بدخیمی در کشور Age-standardized incidence rate of all cancers per 100 000 in female in Iran 2005–2006.

Figure 1. HR (95% CI) of death from dementia associated with weight or BMI in middle age and in old age. From: Adiposity in middle and old age and risk.

Maximum observed HR to achieve statistical significance (two-sided alpha=0.05) and maximum observed HR that satisfies the LL95%CI rule for maximal RB,

Figure 1. Bar plots of age-standardized (world population) death rates per 100 000 persons for the year 2014 (blue, ... Figure 1. Bar plots of age-standardized.

Figure 1 Mechanism of mortality benefit associated with radial access

Figure 1. Survival curves from a hypothesized clinical trial randomizing patient to standard of care with and without ... Figure 1. Survival curves from.

Figure 1 Cumulative late adjusted survival in cardiac resynchronization therapy defibrillator and pacemaker patients. ... Figure 1 Cumulative late adjusted.

Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology.

Figure 1. Relationships among microsatellite instability (MSI; letter A indicates the group with MSI), high tumour ... Figure 1. Relationships among microsatellite.

Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology.

Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology.

Figure 1. Oncoprint of selected pathogenic alterations detected in ctDNA. Unless provided in the caption above, the following copyright applies to the.

Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology.

Figure 2. Biomarkers for prediction of differences in PFS and objective response rate between GP and GT arm in patients ... Figure 2. Biomarkers for prediction.

Figure 1. Sequential programmed death-ligand-1 (PD-(L)1) blockade and osimertinib schema of patients who developed ... Figure 1. Sequential programmed.

Figure 1. Longitudinal measures of HIV persistence and immunologic phenotype/function during anti-PD-1 therapy are ... Figure 1. Longitudinal measures.

Figure 1 Grant agencies and charitable foundations supporting Plan S.

Comparison of the ESMO-MCBS dual rule and the dual rule with PE thresholds exhibiting similar behaviour: %acceptance of maximal RB (solid line: RB rule)

Figure 1. A summary of phase 3 trials for previously untreated advanced/metastatic NSCLC. AEs, adverse events; Beva, ... Figure 1. A summary of phase 3.

Kaplan-Meier curves for PFS (panel A) and OS (panel B) of patients with mTCC receiving an anti-EGFR based therapy. mTCC, metastatic transverse colon cancer;

Figure 2. Forest plot of multivariable Cox proportional hazard regression illustrating the impact of chemoradiation ... Figure 2. Forest plot of multivariable.

Kaplan–Meier analysis of PFS and OS in patients with advanced non-small cell lung cancer with adenocarcinoma histology with time since start of first-line.

(A) Survival curves according to clinical response.

Figure 1 ABCDE of primary prevention.2

Figure 1. Forest plot of lung cancer mortality in LDCT trials.

Presentation transcript:

Figure 3. Visualisation of ESMO-MCB scores for curative and non-curative setting. A & B and 5 and 4 represent the grades with substantial improvement. From: A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS) Ann Oncol. 2015;26(8):1547-1573. doi:10.1093/annonc/mdv249 Ann Oncol | © The Author 2015. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oup.com

Figure 1. Use of threshold HR in the ESMO-MCBS exemplified for HR threshold of 0.65. From: A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS) Ann Oncol. 2015;26(8):1547-1573. doi:10.1093/annonc/mdv249 Ann Oncol | © The Author 2015. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oup.com

Figure 2. The correspondence between an HR value and the minimum absolute gain in months considered as beneficial according to the ESMO-MCBS by median survival (OS or PFS) for control. From: A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS) Ann Oncol. 2015;26(8):1547-1573. doi:10.1093/annonc/mdv249 Ann Oncol | © The Author 2015. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oup.com